Gujarat Terce Share Price

Gujarat Terce Laboratories Limited, with its corporate operations in Ahmedabad, functions as a pharmaceutical formulation company. The company was incorporated in 1985. Gujarat Terce Laboratories manufactures branded and generic pharmaceutical products, including tablets, capsules, oral liquids, ointments, and injections covering therapeutic categories such as antibiotics, respiratory, nutraceuticals, gastrointestinal, gynecology, pain therapy, and ayurvedic. The company markets its products through a network of over 180 marketing representatives across 13 Indian states, rooted in the founding principles of compassion and excellence in healthcare. 

Gujarat Terce Laboratories share price on NSE and BSE signifies how market participants react to the company‘s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on demand for branded generic formulations, raw material costs for active pharmaceutical ingredients, production efficiency at its Gujarat facility, and regulatory compliance in the domestic pharmaceutical market. Gujarat Terce Laboratories stock price is influenced by various factors such as earnings, fluctuations in pharmaceutical raw material prices, changes in government pricing policies for medicines, and overall healthcare spending patterns. In the longer run, strategies such as expanding its brand portfolio, launching new products, and strengthening its marketing reach affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements. 

Gujarat Terce Laboratories live share price provides real time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Gujarat Terce Laboratories live price helps in observing short term price volatility and shows how a stock moves relative to the broader BSE healthcare and pharmaceutical indices. 

Furthermore, monitoring Gujarat Terce Laboratories stock price movements helps investors understand real time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short term performance, and respond to news, quarterly results, or sector trends that may influence the company‘s valuation and overall investment outlook. Gujarat Terce Laboratories live price serves as a real-time barometer of trading interest in this small-cap pharmaceutical stock. 

Gujarat Terce Laboratories Limited Company Fundamentals 

a. Company Background

Gujarat Terce Laboratories Limited was incorporated in 1985. The company is engaged in the development, manufacturing, marketing, and distribution of medicines and healthcare products. It operates in the pharmaceutical segment, supplying branded and generic formulations for multiple therapeutic areas. The company has an ISO 9001 certified manufacturing facility and operates as an integrated pharmaceutical company. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and return on equity. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical sector. Overall fundamentals are influenced by pharmaceutical demand, raw material price fluctuations, and regulatory compliance. 

b. Company Product Lines

• Oral Solid Dosages: Manufactures tablets and capsules covering ten different therapeutic categories. 

• Liquid and Semi-Solid Formulations: Produces oral liquids, syrups, ointments, and other liquid dosage forms. 

• Injectable Products: Provides injections for various therapeutic indications. 

• Branded Generics: Offers products under brand names including Acolate, Tynol, Resplash, Ferlit, Z-Oxi, Vitfol, Thyter, Aziter, Codimol, Cefter, and Terflora. 

c. Company Revenue Model

• Domestic Sales: Generates revenue from sales of pharmaceutical products within India through its marketing team across 13 states. 

• Institutional and Bulk Contracts: Supplies products to hospitals and healthcare institutions. 

• Trading Income: Earns revenue from trading of healthcare products. 

d. Geographic Presence

• Corporate Headquarters: Administrative functions based in Ahmedabad, Gujarat, India. 

• Manufacturing Facility: Production unit located in Gujarat, India. 

• Domestic Market: Products supplied across 13 Indian states through a network of over 180 marketing representatives. 

e. Key Milestones

• 1985 – Company Incorporation: Gujarat Terce Laboratories was incorporated as a pharmaceutical manufacturing company. 

• 2000 – Product Portfolio Expansion: The company expanded its product basket to multiple therapeutic categories. 

• 2010 – Quality Certification: The company obtained ISO 9001 certification for its manufacturing processes. 

• 2015 – Brand Development: Gujarat Terce Laboratories developed its branded generic portfolio. 

• 2020 – Marketing Expansion: The company expanded its marketing network to over 180 representatives across 13 states. 

• 2024 – BSE Listing: The company was listed on the BSE SME platform. 

• 2025 – Operational Challenges: Gujarat Terce Laboratories faced headwinds from raw material costs and pricing pressures. 

• 2026 – Financial Performance: The company reported net profit in certain quarters and continued its focus on branded formulations. 

f. Industry Perspective

The Indian pharmaceutical industry is one of the largest in the world, with companies ranging from large multinationals to small-cap specialized manufacturers. Companies in this sector face challenges from raw material price volatility, intense competition, and regulatory scrutiny from bodies like the CDSCO. Gujarat Terce Laboratories, as a small-cap pharmaceutical company with a broad product portfolio and marketing network, must manage production efficiency, quality standards, and pricing pressures effectively. The industry is also affected by government price controls, healthcare spending patterns, and patent regulations. Companies must maintain regulatory compliance while managing costs and competition. These factors collectively influence financial performance and investor perception of firms like Gujarat Terce Laboratories. 

Gujarat Terce Laboratories Limited Stock Market Presence: Listings & Index Representation 

Gujarat Terce Laboratories Limited is listed on the Bombay Stock Exchange with the scrip code 524314. Gujarat Terce Laboratories share price is actively traded on the BSE. The company‘s market presence is within the small-cap segment of the market, specifically on the BSE SME platform. Due to its pharmaceutical focus, Gujarat Terce Laboratories share price today is generally tracked by investors interested in the branded generic pharmaceutical industry. 

Gujarat Terce Laboratories is part of select broad-based and sector-specific stock market indices. The company’s stock finds representation in BSE small-cap and healthcare indices based on its market standing. This presence helps investors track the Gujarat Terce Laboratories relative to other pharmaceutical companies. Gujarat Terce Laboratories stock price is monitored by investors focusing on small-cap pharma firms. Gujarat Terce Laboratories stock price movements also reflect the performance of the broader pharmaceutical sector on the BSE. 

Gujarat Terce Laboratories Limited Stock Performance and Share Price History 

Gujarat Terce Laboratories share price on the BSE reflects its position as a small-cap branded generic pharmaceutical company in India. Its performance is qualitatively driven by factors such as demand for pharmaceutical formulations, management of raw material costs, growth in marketing reach, and the ability to maintain product quality and regulatory compliance. Investors compare Gujarat Terce Laboratories movement with other small-cap pharma companies to assess relative strength. 

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings-driven price changes. Broader sector strength has also supported Gujarat Terce Laboratories at certain times. Beyond operational and sector influences, corporate actions such as the company‘s listing on the BSE SME platform and its focus on branded formulations can significantly affect share price movements by shaping future growth expectations. This shows how strategic initiatives may trigger short term swings, even within a regulatory environment influenced by pharmaceutical pricing policies and raw material cycles. 

While short term movements respond to events and announcements, longer term valuation trends are better captured by Gujarat Terce Laboratories annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger pharmaceutical demand and stable production costs, whereas a significant low aligns with market corrections or sector volatility. These extremes reflect the impact of economic conditions, raw material price fluctuations, and earnings visibility, providing a framework for understanding historical performance. 

Gujarat Terce Laboratories behavior mirrors the trading patterns of a small-cap pharmaceutical company within India’s healthcare ecosystem. The company’s diversified product portfolio spanning multiple therapeutic categories has shaped its price history. Over the past several years, Gujarat Terce Laboratories has experienced periods of sharp gains followed by phases of consolidation. Gujarat Terce Laboratories share price has shown higher volatility compared to larger pharmaceutical companies, reflecting the specific risks of its small-cap business model. 

The company’s performance has closely tracked pharmaceutical demand and raw material costs. Positive momentum appeared during periods of strong demand for branded generics and favourable product mix. However, periods of weak pharmaceutical demand and increased competition have led to consolidation in Gujarat Terce Laboratories. 

Gujarat Terce Laboratories share price has declined for several recurring reasons. A drop in demand for branded generic formulations or lower realizations directly impacts revenue visibility and leads to selling pressure. Changes in government policies on pharmaceutical pricing or raw material import duties can also cause Gujarat Terce Laboratories share price to fall. Increases in active pharmaceutical ingredient costs without matching price hikes squeeze margins, making Gujarat Terce Laboratories share price less attractive. Periods of economic slowdown that affect healthcare spending raise concerns about sales pipelines, leading to price declines. Gujarat Terce Laboratories share price is sensitive to raw material price movements and regulatory changes affecting drug approvals. Broader market sell-offs in small-cap stocks also pull the price down, regardless of the company’s individual performance. Lower prescription volumes or reduced institutional orders directly hurts revenue, resulting in a lower valuation. Gujarat Terce Laboratories share price also faces pressure when the company reports fluctuations in profit margins due to input cost volatility. 

Gujarat Terce Laboratories has seen downward pressure when the company reported fluctuations in net profit and operating margins. Gujarat Terce Laboratories movements often mirror the broader BSE SmallCap and healthcare index trends. Gujarat Terce Laboratories can be impacted by changes in pharmaceutical demand and raw material availability. Gujarat Terce Laboratories has historically shown sensitivity to drug pricing regulations. Gujarat Terce Laboratories may also be affected by the company’s ability to maintain its competitive edge in developing new branded formulations. Gujarat Terce Laboratories performance is closely watched by investors tracking the small-cap pharmaceutical segment on the BSE SME platform. Gujarat Terce Laboratories stock price has moved within a broad range over the last year, reflecting the general market conditions for small-cap pharma companies. 

Gujarat Terce Laboratories Limited Investor Relevance and Role in Portfolio 

Gujarat Terce Laboratories Limited is a holding in select small-cap and pharmaceutical sector portfolios, offering exposure to branded generic formulations, oral solid dosages, and the healthcare space. Its inclusion on the BSE SME platform underscores its importance in India‘s specialized pharmaceutical manufacturing sector. The company’s position as an integrated pharmaceutical company with a broad product portfolio and marketing network, together with its focus on branded generics, makes it a consideration for long term allocations. 

Gujarat Terce Laboratories share price is influenced by the company’s ownership structure. Gujarat Terce Laboratories’s equity is held by promoters and the public. Promoters hold a significant majority stake, reflecting strong internal control. Foreign institutional investors and domestic institutional investors hold relatively small stakes in the company. The public and other retail investors hold the remaining stake. This investor base underscores the company’s role as a holding in retail and select institutional portfolios concentrating on small-cap pharmaceutical manufacturing. 

Beyond fundamentals and ownership, Gujarat Terce Laboratories share price is actively monitored in the cash market segment on the BSE SME platform, where trading volumes and delivery patterns reflect expectations on pharmaceutical demand, raw material costs, and regulatory policy actions. Gujarat Terce Laboratories stock price is available for trading on the BSE SME platform, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements. 

Technical indicators provide additional insight into short term momentum shifts in Gujarat Terce Laboratories share price. While these indicators are primarily used for near term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. Gujarat Terce Laboratories share price has exhibited price movements that correlate with broader small-cap and pharmaceutical sector trends. The company carries a moderate level of debt on its balance sheet. Return on equity and return on capital employed are key reference points for the company’s profitability. Gujarat Terce Laboratories share price is actively monitored for its trading volume and delivery percentage. 

Overall, Gujarat Terce Laboratories demonstrates a higher volatility profile compared to the broader market, with the stock generally considered to have elevated systematic risk. This makes it more sensitive to broader market movements, and it remains highly exposed to sector-specific factors such as pharmaceutical demand, raw material costs, and regulatory changes. Gujarat Terce Laboratories stock price reflects these inherent business risks. Gujarat Terce Laboratories share price can show sharp movements based on quarterly earnings announcements and new product development news. 

Gujarat Terce Laboratories Limited Sectoral Relevance and Peer Positioning 

Gujarat Terce Laboratories Limited sector relevance stems from its four-decade presence in the pharmaceutical industry, its position as an integrated manufacturer of branded and generic formulations, its portfolio covering tablets, capsules, oral liquids, ointments, and injections across multiple therapeutic areas, its network of over 180 marketing representatives across 13 Indian states, its brand portfolio including Acolate, Tynol, Resplash, Ferlit, Z-Oxi, Vitfol, Thyter, Aziter, Codimol, Cefter, and Terflora, and its status as a BSE SME-listed small-cap pharmaceutical player. Peer comparisons with companies like Ind-Swift Laboratories, Panacea Biotec, Alpa Laboratories, Zenotech Laboratories, and other small-cap pharmaceutical firms focus on revenue growth, margin performance, brand strength, and regulatory adherence rather than short term stock moves. These benchmarks help investors assess operational scale, efficiency, and market positioning. Institutional tracking of pharmaceutical policies, healthcare spending, and raw material prices further highlights Gujarat Terce Laboratories positioning within the broader pharmaceutical market. 

Gujarat Terce Laboratories market cap highlights its position as a small-cap player within the pharmaceutical sector. The company’s market capitalization has moved in line with investor perceptions of the company’s growth potential following its focus on branded formulations and marketing expansion. From earlier periods through more recent times, the market cap showed trends as the company broadened its product portfolio. This pattern reflects investor confidence during favourable pharmaceutical demand cycles, followed by consolidation during challenging periods impacted by raw material volatility and regulatory changes. This decrease mirrors the correction in Gujarat Terce Laboratories share price from its higher levels to recent ranges. 

Gujarat Terce Laboratories earnings trajectory demonstrates the impact of its operational execution in a competitive pharmaceutical industry. In recent fiscal years, total income showed variability, influenced by the company’s product sales and marketing reach. The company’s revenue from operations fluctuated, with some quarters showing declines and others showing recovery. Profit after tax shifted from losses to profits in the most recent fiscal year, demonstrating the impact of operational adjustments and cost management. The company has faced headwinds from fluctuating raw material costs, intense competition, and pricing pressures. However, the company continues to focus on its branded generic portfolio and marketing network. Gujarat Terce Laboratories reported net profit for the full fiscal year, indicating some stabilization. These developments illustrate the evolving nature of the pharmaceutical industry and the company’s position within this sector. 

Gujarat Terce Laboratories EPS provides insight into its operational performance and income generation from pharmaceutical formulations. The company reported earnings that varied based on demand cycles and raw material cost fluctuations. The earnings per share has shown variability over time, with positive EPS in the most recent fiscal year after periods of negative earnings, reflecting the inherent volatility of a small-cap pharmaceutical business. The company has a face value of ten rupees per share. 

Gujarat Terce Laboratories P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from pharmaceutical products. The current valuation compared to industry averages indicates how the market assesses the company’s earnings potential. The company’s profit after tax has shown improvement in the most recent fiscal period based on operational performance. The P/E ratio has moved within a range as the stock price fluctuated with earnings visibility. Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a dynamic pharmaceutical industry. 

Summary 

Gujarat Terce Laboratories Limited operates as a branded generic pharmaceutical manufacturer with a broad product portfolio and marketing network across India. The company has served the healthcare sector since its incorporation in 1985. Gujarat Terce Laboratories share price reflects the company‘s performance in the pharmaceutical sector. Gujarat Terce Laboratories stock price is influenced by drug demand, raw material costs, and regulatory policies. Investors consider its product portfolio and marketing reach when evaluating its standing in the small-cap pharmaceutical space.